#43 How to leverage past experience in developing treatments for rare disease. James Mackay, PhD - CEO, Aristea Therapeutics

This episode of BioTech IQ features James Mackay, PhD, Founder and CEO of Aristea Therapeutics. Aristea Therapeutics is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. In particular, their lead asset is addressing palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States that affects about 100,000 people.Don't miss this episode as we discuss James' background and the strategy of Aristea's approach to their current asset.https://aristeatx.com/Check out out more episodes at https://thebiotechiqpodcast.com/Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/

Om Podcasten

Increase your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science, clinical operations, clinical development, safety/PV and more! We address how each function plays an important role in the drug approval process. We also discuss the people that make up these departments. Get ready to hear about cutting edge development and the people who make it happen!